Tonghua Dongbao Pharmaceutical

600867 · SSE · China

Public Market Listing

600867SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Tonghua Dongbao Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Insulin receptorPeptide
Type 2 Diabetes
Phase 2
GLP-1/GIP receptor (dual)Peptide
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 October 2025Topline resultTHDB0206THDB0206 Phase 3 in T1D (NCT07282054) met its primary endpoint
Adocia · Source ↗
25 July 2025Topline resultTHDB0206THDB0206 Phase 3 in T2D (NCT05834868) met its primary endpoint
Adocia · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$410M—$205M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$280M——$5.8Mreport ↗
2023-FY$435M———report ↗